Radius Health, Inc., a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide that is in Phase III clinical trial to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator/degrader, which is in Phase I clinical trial for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator that is in Phase I clinical trial to treat breast cancer. The company has collaborations and license agreements with 3M; Ipsen Pharma SAS; Eisai Co. Ltd.; Duke University; and Teijin Limited, as well as research and development agreements with Nordic Bioscience Clinical Development VII A/S. Radius Health, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:RDUS
CUSIPN/A
Phone617-551-4000
Debt
Debt-to-Equity Ratio1.26
Current Ratio5.39
Quick Ratio5.26
Price-To-Earnings
Trailing P/E Ratio-3.47
Forward P/E Ratio-3.74
P/E GrowthN/A
Sales & Book Value
Annual Sales$22.11 million
Price / Sales41.12
Cash FlowN/A
Price / CashN/A
Book Value$5.43 per share
Price / Book3.68
Profitability
EPS (Most Recent Fiscal Year)($5.80)
Net Income$-254,230,000.00
Net Margins-444.70%
Return on Equity-110.71%
Return on Assets-56.31%
Miscellaneous
Employees561
Outstanding Shares45,480,000
Market Cap$1.02 billion
Radius Health (NASDAQ:RDUS) Frequently Asked Questions
What is Radius Health's stock symbol?
Radius Health trades on the NASDAQ under the ticker symbol "RDUS."
How were Radius Health's earnings last quarter?
Radius Health Inc (NASDAQ:RDUS) posted its quarterly earnings data on Tuesday, August, 7th. The biopharmaceutical company reported ($0.99) EPS for the quarter, topping the consensus estimate of ($1.35) by $0.36. The biopharmaceutical company earned $22.63 million during the quarter, compared to analyst estimates of $20.84 million. Radius Health had a negative net margin of 444.70% and a negative return on equity of 110.71%. View Radius Health's Earnings History.
When is Radius Health's next earnings date?
What price target have analysts set for RDUS?
8 brokers have issued 1-year price objectives for Radius Health's stock. Their predictions range from $25.00 to $59.00. On average, they anticipate Radius Health's stock price to reach $48.6250 in the next twelve months. This suggests a possible upside of 143.2% from the stock's current price. View Analyst Price Targets for Radius Health.
What is the consensus analysts' recommendation for Radius Health?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Radius Health in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Radius Health.
What are Wall Street analysts saying about Radius Health stock?
Here are some recent quotes from research analysts about Radius Health stock:
- 1. Cantor Fitzgerald analysts commented, "TYMLOS Growing the Market. RDUS reported 1Q18 sales of $14.5 mln, up from $7.7 in the prior quarter. The launch is modest, which is not surprising given the specialty market and reimbursement/coverage ramp. What is a positive dynamic, in our view, is the market growth overall, with TYMLOS both capturing market share and growing the market overall for anabolics." (5/11/2018)
- 2. According to Zacks Investment Research, "Radius received a major boost with the approval of Tymlos for the treatment of postmenopausal women with high risk osteoporosis for fracture. Although the osteoporosis market has a great potential as approximately 1.4 million postmenopausal women in the United States experience an osteoporotic fracture each year, Tymlos is expected to face significant competition from Forteo and Prolia. Further, the company suffered a setback when the CHMP issued a negative trend vote on the benefit-risk balance for the MAA for abaloparatide-SC in an oral explanation. The CHMP will therefore adopt a negative opinion on the same. The delay in getting approval in Europe is disappointing given the market potential. The company’s shares have underperformed the industry in the last three months. Meanwhile, estimates are stable ahead of the first-quarter results (scheduled on May 8)." (5/2/2018)
Who are some of Radius Health's key competitors?
Some companies that are related to Radius Health include Ultragenyx Pharmaceutical (RARE), GW Pharmaceuticals PLC- (GWPH), Madrigal Pharmaceuticals (MDGL), Endo International (ENDP), Horizon Pharma (HZNP), Intercept Pharmaceuticals (ICPT), Evotec (EVTCY), Array Biopharma (ARRY), Opko Health (OPK), Blueprint Medicines (BPMC), Heron Therapeutics (HRTX), Akcea Therapeutics (AKCA), Amicus Therapeutics (FOLD), Ironwood Pharmaceuticals (IRWD) and The Medicines (MDCO).
Who are Radius Health's key executives?
Radius Health's management team includes the folowing people:
- Mr. Jesper Høiland, Pres, CEO & Director (Age 58)
- Mr. Jose Carmona, CFO, Sr. VP & Treasurer (Age 46)
- Dr. Gary Hattersley, Chief Scientific Officer & Sr. VP (Age 51)
- Mr. Brent Hatzis-Schoch J.D., Sr. VP, Gen. Counsel & Sec. (Age 53)
- Mr. Brian Nicholas Harvey, Advisor (Age 57)
Has Radius Health been receiving favorable news coverage?
Media stories about RDUS stock have been trending positive this week, Accern Sentiment Analysis reports. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Radius Health earned a media and rumor sentiment score of 0.26 on Accern's scale. They also gave media coverage about the biopharmaceutical company an impact score of 45.99 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future. View Recent Headlines for Radius Health.
Who are Radius Health's major shareholders?
Radius Health's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BB Biotech AG (13.64%), FMR LLC (5.42%), Point72 Asset Management L.P. (2.62%), Voya Investment Management LLC (1.61%), Bank of America Corp DE (0.91%) and Artisan Partners Limited Partnership (0.50%). Company insiders that own Radius Health stock include Brent Hatzis-Schoch, Growth N V Biotech, Jesper Hoiland and Jose Carmona. View Institutional Ownership Trends for Radius Health.
Which institutional investors are selling Radius Health stock?
RDUS stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Point72 Asset Management L.P., TD Asset Management Inc., Alps Advisors Inc. and California Public Employees Retirement System. View Insider Buying and Selling for Radius Health.
Which institutional investors are buying Radius Health stock?
RDUS stock was bought by a variety of institutional investors in the last quarter, including BB Biotech AG, Artisan Partners Limited Partnership, ING Groep NV, Bank of America Corp DE, Senzar Asset Management LLC, Voya Investment Management LLC, Trexquant Investment LP and Schwab Charles Investment Management Inc.. Company insiders that have bought Radius Health stock in the last two years include Brent Hatzis-Schoch, Growth N V Biotech, Jesper Hoiland and Jose Carmona. View Insider Buying and Selling for Radius Health.
How do I buy shares of Radius Health?
Shares of RDUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Radius Health's stock price today?
One share of RDUS stock can currently be purchased for approximately $19.99.
How big of a company is Radius Health?
Radius Health has a market capitalization of $1.02 billion and generates $22.11 million in revenue each year. The biopharmaceutical company earns $-254,230,000.00 in net income (profit) each year or ($5.80) on an earnings per share basis. Radius Health employs 561 workers across the globe.
How can I contact Radius Health?
Radius Health's mailing address is 950 WINTER STREET, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 617-551-4000 or via email at [email protected]
MarketBeat Community Rating for Radius Health (NASDAQ RDUS)
MarketBeat's community ratings are surveys of what our community members think about Radius Health and other stocks. Vote "Outperform" if you believe RDUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RDUS will underperform the S&P 500 over the long term. You may vote once every thirty days.
